Treatment News : An Aspirin a Day to Keep HIV-Related Cervical Cancer Away?

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » January 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


January 19, 2012

An Aspirin a Day to Keep HIV-Related Cervical Cancer Away?

Might an aspirin a day help keep cervical cancer away? Though there aren’t yet any studies indicating it will, researchers have uncovered a biological connection between HIV-associated inflammation and cervical cancer that may be curtailed by the affordable and widely available drug.

According to the team of scientists—investigators associated with New York-Presbyterian Hospital and Weill Cornell Medical Center in Manhattan and other cancer specialists in New York, Qatar and Haiti—aspirin should be evaluated in clinical trials for its ability to prevent cervical cancer in women living with HIV.   

The team’s suggestion is based on a report published in the January 2012 issue of Cancer Prevention Research. According to the paper authored by Daniel Fitzgerald, MD, of Weill Cornell Medical Center and his colleagues, the simple and inexpensive solution has the potential to provide enormous benefit for women living with HIV in the Caribbean, Latin America and Africa, who suffer from a disproportionately high rate of cervical cancer death. 

“These young patients, many of whom were mothers and the sole support for their families, had worked hard to have their HIV controlled with antiretroviral therapy, only to develop and die from cervical cancer,” says Fitzgerald in an accompanying announcement.

According to experiments conducted by Fitzgerald’s group, HIV was found to increase production of the COX-2/prostaglandin E2 (PGE2) inflammatory pathway in cervical tissue samples from Haitian women who were HIV positive.

The researchers examined levels of COX-2 and PGE-M—a stable metabolite of PGE2—in three groups of women and found increased levels of both molecules in 13 HIV-positive women who were coinfected human papillomavirus (HPV), the virus primarily responsible for cervical cancer. COX-2 and PGE-M were also elevated in 18 women who were HIV positive but negative for HPV; levels were lowest in 17 women negative for both HIV and HPV.

The findings confirm two widely accepted scientific facts: That HIV causes chronic inflammation and that PGE2, which is elevated during inflammation, is associated with an increased risk of cancer. The research also succeeded in taking things one step further, documenting for the first time that HIV ramps up production of PGE2 in cervical tissue.

This may help explain why HIV-positive women are five times more likely to develop invasive cervical cancer than HIV-negative women, the researchers note. It also suggests that inhibitors of the COX-2 molecule (which contributes to the production of PGE2) might break the link between HIV and cervical cancer.

Aspirin is one of the cheapest and most effective COX inhibitors available throughout the world.

The researchers conclude that future studies will be needed to determine whether aspirin or aspirin-like agents—known inhibitors of COX/prostaglandin production—can reduce the risk of cervical cancer in high-risk populations of women living with both HIV and HPV.

Search: aspirin, cervical cancer, human papillomavirus, HPV, cox-2, prostaglandin, PGE2, Fitzgerald, Cornell, Haiti

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.